Category: CRG actions

New consultation: CRG actions September 2024

September 24, 2024

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the September 2024 CRG meeting. Actions in this consultation include:

  • Pylera (metronidazole / tetracycline / bismuth) – grey and green. See also separate consultation on Pylera position statement.
  • H. pylori eradication – align formulary advice to BNF regiment
  • Febuxostat for gout – green
  • Abaloparatide for osteoporosis – RED
  • Burosumab for X-linked hypophosphataemia – RED
  • Relugolix for hormone-sensitive prostate cancer – AMBER
  • Linzagolix for uterine fibroids – green (specialist advice)
  • Risankizumab for ulcerative colitis – RED
  • Hydrocortisone IM for adrenal crisis – green (specialist advice)

All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.

This consultation will run for six weeks and closes at 5pm on Thursday 26th September 2024. To take part, visit the consultations page.

New consultation: CRG actions July 2024

July 18, 2024

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the July 2024 CRG virtual meeting. Actions in this consultation include:

  • Carbimazole 5mg & 20mg tablets – GREEN
  • Budesonide 3mg gastro-resistant capsules – GREEN (following specialist advice)
  • Voxeletor for haemolytic anaemia caused by sickle cell disease – RED
  • Tafamadis for transthyretin amyloidosis with cardiomyopathy – RED

All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.

This consultation will run for six weeks and closes at 5pm on Thursday 29th August 2024. To take part, visit the consultations page.

New consultation: CRG actions June 2024

June 14, 2024

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the June 2024 CRG meeting. Actions in this consultation include:

  • Sunscreens for ACBS conditions – discontinued products to be removed from formulary and replaced with Anthelios SPF 50+ lotion (first choice) and Uvistat Suncream SPF 50 (alternative)
  • Remdesivir and tixagevimab plus cilgavimab – RED
  • Atogepant for treating migraine – Green (specialist advice)
  • Setmelanotide – RED

All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.

This consultation will run for six weeks and closes at 5pm on Friday 5th July 2024. To take part, visit the consultations page.

New consultation: CRG actions May 2024

May 24, 2024

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the May 2024 CRG meeting. Actions in this consultation include:

  • Levomepromazine 6.25mg tablets – green, alternative option where small doses are required and tablet splitting is not appropriate
  • Phenobarbital 15mg/5ml elixir – green (specialist advice) and grey (criterion 1), only for select adult patients for whom ethanol consumption is safe and appropriate. Not for use in children.
  • Bowl cleansing preparations – red, and product list updated to Plenvu, sodium picosulfate with magnesium citrate, and Klean-Prep
  • FreeStyle Libre 2 plus and Dexcom One plus – add as additional options for new and existing patients

All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.

This consultation will run for six weeks and closes at 5pm on Friday 5th July 2024. To take part, visit the consultations page.

New consultation: CRG actions April 2024

April 12, 2024

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the April 2024 CRG meeting. Actions in this consultation include:

  • Lamotrigine tablets – green specialist advice for bipolar disorder
  • Doxylamine / pyridoxine for nausea and vomiting in pregnancy – removed from grey list and made a first choice option alongside cyclizine and prochlorperazine
  • Levemir InnoLet and Insulatard InnoLet – remove from formulary following discontinuation of the products
  • Buprenorphine prolonged release solution for injection (Buvidal) – add to formulary as alternative to methadone and oral buprenorphine
  • Fluocinolone intravitreal implant – RED
  • Dupilumab for prurigo nodularis – DNP
  • Etrasimod for ulcerative colitis – RED
  • Ritlecitinib for alopecia areata – RED
  • Satralizumab for neuromyelitis optica spectrum disorders – DNP
  • Sebelipase alfa for lysosomal acid lipase deficiency – DNP

All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.

This consultation will run for six weeks and closes at 5pm on Friday 24th May 2024. To take part, visit the consultations page.

New consultation: CRG actions March 2024

March 14, 2024

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the March 2024 CRG meeting. Actions in this consultation include:

  • Doxazosin 8mg immediate-release tablets – DNP
  • Atropine 1% eye drops and minims for hypersalivation – GREEN (following specialist advice)
  • Paliperidone palmitate 700mg & 1000mg prolonged-release suspension for injection – add to formulary as AMBER (see also separate consultation on updated shared care protocol)
  • Add belumosudil as RED

All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.

This consultation will run for six weeks and closes at 5pm on Thursday 28th March 2024. To take part, visit the consultations page.

New consultation: CRG actions February 2024

February 16, 2024

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at their February 2024 meeting. Actions in this consultation include:

  • Riluzole 50mg orodispersible tablets added as AMBER
  • Diclofenac 50mg tablets made 3rd line choice, after ibuprofen and naproxen
  • Sebeliplase alfa added as RED

All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.

This consultation will run for six weeks and closes at 5pm on Thursday 28th March 2024. To take part, visit the consultations page.

Consultation: actions from September 2023 CRG meeting

September 15, 2023

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at their September 2023 meeting. Actions in this consultation include:

  • Tadalafil 5mg once daily – remove from DNP list and assign GREEN RAG status
  • Herbal treatments – DNP listing amended to “herbal treatments and other natural products”, in line with NHS England guidance
  • Cipaglucosidase alfa – add to formulary as RED

All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.

The consultation will run for six weeks and closes at 5pm on Friday 27th October 2023. To take part, visit the consultations page.

Consultation: actions from August 2023 CRG meeting

August 11, 2023

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at their August 2023 meeting. Actions in this consultation include:

  • Sodium chloride 5% eye drops – RED
  • Bempedoic acid – comments sought regarding a change to GREEN
  • Steroid eye drops (betamethasone 0.1%, dexamethasone 0.1%, prednisolone 0.03%, 0.1%, 0.5% & 1%, fluorometholone 0.1%) – GREEN (specialist initiation)
  • Rimegepant for preventing migraine – GREEN (specialist initiation) OR GREEN (specialist advice)
  • Semaglutide for overweight and obesity in young people aged 12-17 years – Do Not Prescribe.

All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.

The consultation will run for six weeks and closes at 5pm on Friday 22nd September 2023. To take part, visit the consultations page.

Consultation: actions from July CRG meeting

July 18, 2023

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at their July 2023 meeting. Actions in this consultation include:

  • Bulevirtide for chronic hepatitis D – add to formulary as RED
  • Esketamine for major depressive disorder in adults at imminent risk of suicide – update existing DNP listing to include this indication
  • Dapagliflozin for chronic heart failure with preserved or mildly reduced ejection fraction – add to formulary as GREEN (following specialist advice)
  • Upadacitinib for Crohn’s disease – add to formulary as RED
  • Deucravactinib for plaque psoriasis – add to formulary as RED
  • Emollient bath additives – update DNP listing to include reference to new NICE ‘do not do’ recommendation

All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.

The consultation will run for six weeks and closes at 5pm on Tuesday 29th August 2023. To take part, visit the consultations page.